TITLE

Molecular screening of Chinese medicinal plants for progestogenic and anti-progestogenic activity

AUTHOR(S)
AHMED, HM MANIR; JAN-YING YEH; YI-CHIA TANG; WINSTON TENG-KUEI CHENG; BOR-RUNG OU
PUB. DATE
June 2014
SOURCE
Journal of Biosciences;Jun2014, Vol. 39 Issue 3, p453
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Estrogen and progestins have adverse effects, and many of these adverse effects are caused by progestins. Due to this, many women choose to use botanical alternatives for hormone replacement therapy, which does not trigger steroidogenic properties. Therefore, it is necessary to screen these herbs for progestogenic and anti-progestogenic properties. Extract of 13 Chinese medicinal plants were analysed for progestogenic and anti-progestogenic activities by using progesterone response element-driven luciferase reporter gene bioassay. MTT assay was carried out to investigate the cytotoxic effect of herb extract on PAE cells. Among the 13 herbs, Dipsacus asperoides extract exhibited progestogenic activity, and 10 species - Cortex eucommiae, Folium artemisiae argyi, Glycyrrhiza uralensis, Angelica sinensis, Atractylodes macrocephala koidz, Scutellaria baicalensis, Cuscuta chinensis, Euscaphis japonica, Ailanthus altissima, and Dioscorea opposita - were recognized to have anti-progestogenic like activities. Extract of Dipsacus asperoides demonstrated dose-dependent progestogenic activity, and the progestogenic activity of 100 µg/mL extracts was equivalent to 31.45 ng/mL progesterone activity. Herbs extracts that exhibited anti-progestogenic-like activity also inhibited the 314.46 ng/mL progesterone activity in a dose-response manner. None of the herb extracts shown significant toxic effect on PAE cells at 40-100 µg/mL compared to control. This discovery will aid selection of suitable herbs for hormone replacement therapy.
ACCESSION #
95978506

 

Related Articles

  • Development of Androgen- and Estrogen-Responsive Bioassays, Members of a Panel of Human Cell Line-Based Highly Selective Steroid-Responsive Bioassays. Sonneveld, Edwin; Jansen, Hendrina J.; Riteco, Jacoba A. C.; Brouwer, Abraham; van der Burg, Bart // Toxicological Sciences;Jan2005, Vol. 83 Issue 1, p136 

    We have established highly sensitive and specific androgen and estrogen reporter cell lines which we have named AR (androgen receptor) and ERα (estrogen receptor alpha) CALUX® (Chemically Activated LUciferase eXpression), respectively. Both bioassays are member of a panel of CALUX reporter...

  • NIH Findings: Controversy of Hormone Replacement Therapy. Sztykowski, Tadeusz; Burke, Robert E. // American Acupuncturist;Fall2002, Vol. 28, p16 

    Focuses on the controversy behind the use of combined estrogen and progestin in healthy menopausal women. Examination of the effect of Prempro on the prevention of heart disease; Association of the effects with the risk of breast and colon cancer; Decrease of libido among the menopausal women.

  • Study confirms value of progestin-estrogen combination.  // Mayo Clinic Health Letter;May1996, Vol. 14 Issue 5, p4 

    Presents information from a study on the value of progestin and estrogen. Progestin taken with estrogen offsets the risk of uterine cancer; Uses of estrogen; What progestin is.

  • Estrogen plus progestin increased coronary heart disease and breast cancer events in postmenopausal women. Lowe, Julia // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p41 

    Presents information on a study that investigated the risks and benefits of estrogen plus progestin in healthy postmenopausal women. Design of the study; Analysis of the incidence of diseases between the placebo-controlled trial versus estrogen plus progestin; Rate of unfavorable and favorable...

  • Bulletin.  // Self;Apr97, Vol. 19 Issue 4, p47 

    Reports on estrostep as the first pill to combine low, gradually increasing amounts of estrogen with a low constant dose of progestin. Lower risk of nausea and breakthrough breeding as advantage.

  • New labeling approved for estrogen products.  // Formulary;Feb2003, Vol. 38 Issue 2, p82 

    Reports on the U.S. Food and Drug Administration's labeling changes for estrogen and estrogen with progestin therapies for use by postmenopausal women. Inclusion of a warning emphasizing the increase risk for heart diseases, heart attacks and breast cancer.

  • Sugar, Fat and the Pill. Woeber, Kenneth A. // Annals of Internal Medicine;Feb67, Vol. 66 Issue 2, p446 

    Editorial. Examines the mechanisms of estrogens and progestagens given in combination for suppressing ovulation. Clinical evidence of the contraceptive functions of these agents; Experiments on glucose-tolerance curves; Effects of contraceptive agents on lipid metabolism.

  • CANCER. PARK, ALICE // Time International (Asia Edition);2/14/2011, Vol. 177 Issue 6, p11 

    The article reports on results of a trial in Great Britain which confirms the risk of breast cancer in women who use a combination estrogen and progestin pills.

  • The French ESTHER Study of VTE. Speroff, Leon // OB/GYN Clinical Alert;May2007, Vol. 24 Issue 1, p6 

    The EStrogen and THromboEmbolism Risk (ESTHER) study is a case-control study performed with cases from 8 French hospitals and controls from the general population. The results were as follows: The authors concluded that transdermal estrogen is not associated with an increased risk of VTE, and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics